Co-Authors
This is a "connection" page, showing publications co-authored by JACK PHAN and GARY BRANDON GUNN.
Connection Strength
3.155
-
Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience. Head Neck. 2023 07; 45(7):1692-1703.
Score: 0.227
-
Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head Neck. 2021 11; 43(11):3331-3344.
Score: 0.200
-
Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT. J Appl Clin Med Phys. 2021 Jan; 22(1):37-44.
Score: 0.192
-
Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020 11; 42(11):3326-3335.
Score: 0.187
-
Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head Neck. 2020 08; 42(8):2137-2144.
Score: 0.183
-
A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
Score: 0.179
-
Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Phys Imaging Radiat Oncol. 2019 Apr; 10:29-34.
Score: 0.172
-
Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. 2020 Jan; 28(1):261-269.
Score: 0.171
-
Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head Neck. 2017 10; 39(10):2079-2087.
Score: 0.152
-
Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. J Appl Clin Med Phys. 2016 05 08; 17(3):180-189.
Score: 0.140
-
Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1117-31.
Score: 0.138
-
Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head Neck. 2016 04; 38 Suppl 1:E2091-9.
Score: 0.138
-
Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
Score: 0.137
-
Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiother Oncol. 2015 Oct; 117(1):132-8.
Score: 0.134
-
Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E925-33.
Score: 0.132
-
Sinonasal NUT carcinoma: A consecutive case series and systematic review. Head Neck. 2024 01; 46(1):29-36.
Score: 0.058
-
Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. Int J Part Ther. 2021; 8(1):319-327.
Score: 0.050
-
Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020 01; 142:133-139.
Score: 0.044
-
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
Score: 0.044
-
Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. Clin Transl Radiat Oncol. 2019 Sep; 18:120-127.
Score: 0.043
-
Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope. 2020 01; 130(1):86-93.
Score: 0.042
-
Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. Oral Oncol. 2019 01; 88:66-74.
Score: 0.042
-
Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clin Transl Radiat Oncol. 2018 Nov; 13:19-23.
Score: 0.041
-
Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiat Oncol. 2017 Aug 15; 12(1):129.
Score: 0.038
-
Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol. 2017 09; 72:90-97.
Score: 0.038
-
Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck. 2017 04; 39(4):633-638.
Score: 0.036
-
Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. 2016 11 15; 122(21):3411-3412.
Score: 0.035
-
Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. 2016 06 01; 122(11):1702-7.
Score: 0.035
-
Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 04; 38 Suppl 1:E1554-61.
Score: 0.034
-
A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):344-352.
Score: 0.033
-
Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. Radiother Oncol. 2014 Sep; 112(3):321-5.
Score: 0.031
-
Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. Cancer. 2014 Oct 01; 120(19):3082-8.
Score: 0.031